Abstract
Focal segmental glomerulosclerosis, or FSGS, is a proteinuric kidney disease named based on the pattern of scarring seen on a kidney biopsy which can result from many different causes/reasons. FSGS has become the most common primary glomerular disease leading to end-stage kidney disease in the United States and is observed in approximately one-third of biopsies done for idiopathic nephrotic syndrome (Appel and D’Agati, Comprehensive clinical nephrology, 5th edn, 2015, pp. 218–230; D’Agati et al., N Engl J Med 365(25):2398–2411, 2011; Korbet, J Am Soc Nephrol 23(11):1769–1776, 2012). There is still much we do not know about the disease process as a whole, yet our understanding of how a similar final pattern of injury can develop from a multitude of etiologies has expanded. Due to the number of causes for FSGS and our ever expanding knowledge of this disorder, determining the reason for the disease and providing appropriate treatment remains a challenge.
In this chapter, we will discuss the known causes for this disease and how they are believed to lead to a similar pattern of injury. We will also define the histological types of FSGS and how they can help determine the cause of the injury. Finally, we will describe the clinical features of this disease and discuss potential treatment options.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACEi:
-
Angiotensin converting enzyme inhibitor
- APOL1:
-
Apolipoprotein L1
- ARB:
-
Angiotensin receptor blocker
- BP:
-
Blood pressure
- CLC-1:
-
Cardiotrophin-like cytokine 1
- CNI:
-
Calcineurin inhibitor
- COQ:
-
Coenzyme Q
- ESRD :
-
End stage renal disease
- FSGS:
-
Focal segmental glomerulosclerosis
- HAN:
-
Heroin associated nephropathy
- HIVAN:
-
Human immunodeficiency virus associated nephropathy
- KDIGO :
-
Kidney disease improving global outcomes
- MAP:
-
Mean arterial pressure
- MMF:
-
Mycophenolate mofetil
- mTOR:
-
Mechanistic target of rapamycin
- RAAS:
-
Renin angiotensin aldosterone system
- suPAR:
-
Soluble urokinase plasminogen activator receptor
- TGF-β:
-
Transformimg growth factor beta
- TNFα:
-
Tumor necrosis factor alpha
- TRPC6:
-
Transient receptor potential cation channel 6
References
Appel GB, D’Agati VD. Primary and secondary (non-genetic) causes of focal and segmental glomerulosclerosis. In: Johnson RJ, Feehally J, Floege J, editors. Comprehensive clinical nephrology. 5th ed. Philadelphia: Elsevier Saunders; 2015. p. 218–30.
D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–411.
Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76–87.
Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant. 2015;30(3):375–84.
Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet. 1972;2(7773):343–8.
Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992;92(4):375–83.
Chang JW, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, et al. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation. 2012;93(12):1238–44.
Le Berre L, Godfrin Y, Lafond-Puyet L, Perretto S, Le Carrer D, Bouhours JF, et al. Effect of plasma fractions from patients with focal and segmental glomerulosclerosis on rat proteinuria. Kidney Int. 2000;58(6):2502–11.
Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol. 1984;22(1):32–8.
Kemper MJ, Wolf G, Muller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med. 2001;344(5):386–7.
Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994;330(1):7–14.
Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int. 2004;17(3):151–7.
Rea R, Smith C, Sandhu K, Kwan J, Tomson C. Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16(2):416–7.
Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648–9.
Sellier-Leclerc AL, Duval A, Riveron S, Macher MA, Deschenes G, Loirat C, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol. 2007;18(10):2732–9.
McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115–21.
Savin VJ, Sharma M, McCarthy ET, Sharma R, Reddy S, Dong J, et al. Cardiotrophin like cytokine-1: candidate for the focal glomerular sclerosis permeability factor. J Am Soc Nephrol. 2008;19:59A.
Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55–63.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60.
Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013;96(7):649–56.
Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85(3):636–40.
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12):2051–9.
Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013;96(4):394–9.
Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol. 2014;25(8):1662–8.
Rood IM, Deegens JK, Wetzels JF. Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transplant. 2012;27(3):882–90.
Pollak MR. Familial FSGS. Adv Chronic Kidney Dis. 2014;21(5):422–5.
Brown EJ, Pollak MR, Barua M. Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney Int. 2014;85(5):1030–8.
Gasser DL, Winkler CA, Peng M, An P, McKenzie LM, Kirk GD, et al. Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype, and independently, with a decreased content of coenzyme Q10. Am J Physiol Renal Physiol. 2013;305(8):F1228–38.
Korkmaz E, Lipska-Zietkiewicz BS, Boyer O, Gribouval O, Fourrage C, Tabatabaei M, et al. ADCK4-associated glomerulopathy causes adolescence-onset FSGS. J Am Soc Nephrol. 2016;27(1):63–8.
Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175–84.
Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185–92.
Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345–50.
Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 2010;78(7):698–704.
Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, et al. APOL1 kidney disease risk variants: an evolving landscape. Semin Nephrol. 2015;35(3):222–36.
Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–37.
Johnstone DB, Shegokar V, Nihalani D, Rathore YS, Mallik L, Ashish, et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One. 2012;7(12):e51546.
Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Perez-Morga D. The trypanolytic factor of human serum. Nat Rev Microbiol. 2006;4(6):477–86.
Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science. 2005;309(5733):469–72.
Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–5.
Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol. 2014;307(3):F326–36.
Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014;312(20):2115–25.
Rao TK, Nicastri AD, Friedman EA. Natural history of heroin-associated nephropathy. N Engl J Med. 1974;290(1):19–23.
Friedman EA, Tao TK. Disappearance of uremia due to heroin-associated nephropathy. Am J Kidney Dis. 1995;25(5):689–93.
Lan X, Rao TK, Chander PN, Skorecki K, Singhal PC. Apolipoprotein L1 (APOL1) Variants (Vs) a possible link between Heroin-associated Nephropathy (HAN) and HIV-associated Nephropathy (HIVAN). Front Microbiol. 2015;6:571.
Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21(1):163–72.
Sakarcan A, Thomas DB, O’Reilly KP, Richards RW. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol. 2002;17(4):290–2.
Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol. 2009;296(2):F418–26.
Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis. 1999;33(4):658–66.
Nadasdy T, Allen C, Zand MS. Zonal distribution of glomerular collapse in renal allografts: possible role of vascular changes. Hum Pathol. 2002;33(4):437–41.
Meehan SM, Pascual M, Williams WW, Tolkoff-Rubin N, Delmonico FL, Cosimi AB, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation. 1998;65(9):1192–7.
Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11(11):2079–87.
Khatua AK, Taylor HE, Hildreth JE, Popik W. Non-productive HIV-1 infection of human glomerular and urinary podocytes. Virology. 2010;408(1):119–27.
Zhong J, Zuo Y, Ma J, Fogo AB, Jolicoeur P, Ichikawa I, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 2005;68(3):1048–60.
Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11(3):150–60.
Leventhal JS, Ross MJ. Pathogenesis of HIV-associated nephropathy. Semin Nephrol. 2008;28(6):523–34.
Chandra P, Kopp JB. Viruses and collapsing glomerulopathy: a brief critical review. Clin Kidney J. 2013;6(1):1–5.
Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307(11):652–9.
Rennke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis. 1989;13(6):443–56.
Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012;23(11):1769–76.
Hogan J, Radhakrishnan J. The treatment of idiopathic focal segmental glomerulosclerosis in adults. Adv Chronic Kidney Dis. 2014;21(5):434–41.
Inokuchi S, Shirato I, Kobayashi N, Koide H, Tomino Y, Sakai T. Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis. Kidney Int. 1996;50(4):1278–87.
Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992;42(1):148–60.
Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, et al. Podocyte injury damages other podocytes. J Am Soc Nephrol. 2011;22(7):1275–85.
D’Agati VD. Podocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts). Kidney Int. 2008;73(4):399–406.
D’Agati V. Podocyte injury can be catching. J Am Soc Nephrol. 2011;22(7):1181–3.
Ichikawa I, Ma J, Motojima M, Matsusaka T. Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens. 2005;14(3):205–10.
Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ. Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int. 2015;88(5):999–1012.
El Nahas M, Khwaja A. Epidemiology, natural history, and pathophysiology of chronic kidney disease. In: Johnson RJ, Feehally J, Floege J, editors. Comprehensive clinical nephrology. Philadelphia: Elsevier Saunders; 2015. p. 923–7.
Smeets B, Moeller MJ. Parietal epithelial cells and podocytes in glomerular diseases. Semin Nephrol. 2012;32(4):357–67.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941–52.
Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131–47.
Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, et al. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol. 2002;161(6):2179–93.
Inagi R, Nangaku M, Onogi H, Ueyama H, Kitao Y, Nakazato K, et al. Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. Kidney Int. 2005;68(6):2639–50.
D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–82.
D’Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int. 1994;46(4):1223–41.
Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10(8):445–54.
Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, Weening JJ, et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 2008;74(12):1568–76.
Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–31.
Bahiense-Oliveira M, Saldanha LB, Mota EL, Penna DO, Barros RT, Romao-Junior JE. Primary glomerular diseases in Brazil (1979–1999): is the frequency of focal and segmental glomerulosclerosis increasing? Clin Nephrol. 2004;61(2):90–7.
Kazi JI, Mubarak M, Ahmed E, Akhter F, Naqvi SA, Rizvi SA. Spectrum of glomerulonephritides in adults with nephrotic syndrome in Pakistan. Clin Exp Nephrol. 2009;13(1):38–43.
Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis. 2003;42(6):1107–13.
Dragovic D, Rosenstock JL, Wahl SJ, Panagopoulos G, DeVita MV, Michelis MF. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol. 2005;63(1):1–7.
Hanko JB, Mullan RN, O’Rourke DM, McNamee PT, Maxwell AP, Courtney AE. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009;24(10):3050–4.
Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, Kim BS, et al. Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant. 2009;24(8):2406–10.
Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815–25.
Swaminathan S, Leung N, Lager DJ, Melton 3rd LJ, Bergstralh EJ, Rohlinger A, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol. 2006;1(3):483–7.
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061–8.
Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25(4):534–42.
Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM. 2005;98(6):443–9.
Beaufils H, Alphonse JC, Guedon J, Legrain M. Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron. 1978;21(2):75–85.
Brown CB, Cameron JS, Turner DR, Chantler C, Ogg CS, Williams DG, et al. Focal segmental glomerulosclerosis with rapid decline in renal function (“malignant FSGS”). Clin Nephrol. 1978;10(2):51–61.
Korbet SM, Schwartz MM, Lewis EJ. The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine. 1986;65(5):304–11.
Velosa JA, Holley KE, Torres VE, Offord KP. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc. 1983;58(9):568–77.
Stokes MB, D’Agati VD. Morphologic variants of focal segmental glomerulosclerosis and their significance. Adv Chronic Kidney Dis. 2014;21(5):400–7.
Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006;69(5):920–6.
Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169–77.
Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med. 1987;82(5):938–44.
Valeri A, Barisoni L, Appel GB, Seigle R, D’Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int. 1996;50(5):1734–46.
Schwartz MM, Evans J, Bain R, Korbet SM. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol. 1999;10(9):1900–7.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2: 139–274.
Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int. 2002;62(6):2301–10.
Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant. 2008;23(6):1926–30.
Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol. 2001;56(2):89–95.
Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19(12):3062–7.
Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8(12):1326–32.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59(4):1484–90.
Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868–78.
Ren H, Shen P, Li X, Pan X, Zhang W, Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol. 2013;37(1):84–90.
Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207–12.
Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8(12):2072–81.
Leca N. Focal segmental glomerulosclerosis recurrence in the renal allograft. Adv Chronic Kidney Dis. 2014;21(5):448–52.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Dylewski, J., Blaine, J. (2016). Focal Segmental Glomerulosclerosis and Its Pathophysiology. In: Blaine, J. (eds) Proteinuria: Basic Mechanisms, Pathophysiology and Clinical Relevance. Springer, Cham. https://doi.org/10.1007/978-3-319-43359-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-43359-2_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43357-8
Online ISBN: 978-3-319-43359-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)